State-of-the-art strategies to prioritize Mycobacterium tuberculosis drug targets for drug discovery using a subtractive genomics approach

Tuberculosis remains one of the causes death from a single infectious bacterium. The inappropriate use antibiotics and patients’ non-compliance among other factors drive emergence drug-resistant tuberculosis. Multidrug-resistant extensively strains tuberculosis pose significant challenges to current treatment regimens, as their reduced efficacy against these limits successful patient outcomes. Furthermore, limited effectiveness associated toxicity second-line drugs further compound issue. Moreover, scarcity novel pharmacological targets subsequent decline in number anti-TB compounds drug development pipeline has hindered new therapies. As result, researchers need develop innovative approaches identify potential drugs. evolution technology breakthrough omics data allow computational biology approaches, for example, metabolomic analysis uncover structured-based design. role metabolism pathogen development, growth, survival, infection been established. Therefore, this review focuses on M. tb metabolic network hub target identification highlights step-by-step subtractive genomics approach prioritization.